Sign up to save your podcasts
Or
Share Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market
We welcome back Veru's CEO Mitch Steiner to our latest WTR Healthcare Happenings podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.
View all episodes
By Joe BrunettoWe welcome back Veru's CEO Mitch Steiner to our latest WTR Healthcare Happenings podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.